Immunotherapy

Immunology·MeSH: Triple Negative Breast Neoplasms

8 drugs in development·7 companies·13 clinical trials

Drug Pipeline by Phase

Phase 2(3)

Drug	Company
Telaglenastat (CB-839)	Calithera Biosciences, Inc. (CALA)
Tricalm Hydrogel	Clearside Biomedical, Inc. (CLSDQ)
vopratelimab	Jounce Therapeutics, Inc. (JNCE)

Phase 1(2)

Drug	Company
chs-114	VACCINEX, INC. (VCNX)
ITI-1020	Intra-Cellular Therapies, Inc. (ITCI)

Preclinical(2)

Drug	Company
enLIGHTEN™ Discovery Platform (platform-level entry)	Candel Therapeutics, Inc. (CADL)
primary immune response	Biodesix Inc. (BDSX)

Phase 4(1)

Drug	Company
Triamcinolone acetonide 0.1% cream	Clearside Biomedical, Inc. (CLSDQ)

BioSniper tracks 8 drugs in development for Immunotherapy across 7 companies.

There are 13 clinical trials targeting Immunotherapy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.